Cannabinoid-related Agents in the Treatment of Anxiety Disorders: Current Knowledge and Future Perspectives
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Rich evidence has shown that cannabis products exert a broad gamut of effects on emotional regulation. The main psychoactive ingredient of hemp, Δ9-tetrahydrocannabinol (THC), and its synthetic cannabinoid analogs have been reported to either attenuate or exacerbate anxiety and fear-related behaviors in humans and experimental animals. The heterogeneity of cannabis-induced psychological outcomes reflects a complex network of molecular interactions between the key neurobiological substrates of anxiety and fear and the endogenous cannabinoid system, mainly consisting of the arachidonic acid derivatives anandamide and 2-arachidonoylglycerol (2-AG) and two receptors, respectively termed CB1 and CB2. The high degree of interindividual variability in the responses to cannabis is contributed by a wide spectrum of factors, including genetic and environmental determinants, as well as differences in the relative concentrations of THC and other alkaloids (such as cannabidiol) within the plant itself. The present article reviews the currently available knowledge on the herbal, synthetic and endogenous cannabinoids with respect to the modulation of anxiety responses, and highlights the challenges that should be overcome to harness the therapeutic potential of some of these compounds, all the while limiting the side effects associated with cannabis consumption. In addition the article presents some promising patents on cannabinoid-related agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“Both objectives were met around 30 years later, with the characterization of the two major cannabinoid receptors, CB1 [29] and CB2 [30] as well as the discovery of two most prominent endocannabinoids Narachidonoylethanolamine (commonly named anandamide from the Sanskrit ānanda, bliss) [31] and 2-arachidonoylglycerol (…”
BackgroundCannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 1×
“[37-41].”
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 1×
“[37-41].”
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 17×
“The prototypical FAAH inhibitor URB597 (Fig.”
BackgroundInfluentialEndogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607 · cited 1×
“Presynaptic CB1 receptors are posited to serve critical functions for the regulation of synaptic plasticity and neurotransmitter release; in particular, they mediate the depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE), consisting in the reduction of γ-a…”
BackgroundImmunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586 · cited 1×
“CB1 receptors are typically located on presynaptic terminals [42,43], but they have also been identified in postsynaptic locations [44,45].”
BackgroundIdentification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Caspi, A., Moffitt, T. E., Cannon, M., McClay, J., Murray, R., Harrington, H., Taylor, A., Arseneault, L., Williams, B., Braithwaite, A., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.026 · Cited by 1,409
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 1×
“4) has been shown to reduce anxiety-like behaviors in rats, in a rimonabant-sensitive fashion [155,163,215-217].”
Background
Cited by
New approaches and challenges to targeting the endocannabinoid system
Di Marzo, V. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.115 · Cited by 480
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users
Bonn-Miller, M. O., Boden, M. T., Bucossi, M. M., & Babson, K. A. (2014) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2013.821477 · Cited by 281
A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol
Sultan, S. R., Millar, S. A., England, T. J., & O'Sullivan, S. E. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00081 · Cited by 95
Endocannabinoid signaling in social functioning: an RDoC perspective
Karhson, D. S., Hardan, A. Y., & Parker, K. J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.169 · Cited by 62
Metadata
- Authors
- Tambaro, S., & Bortolato, M.
- Venue
- Recent Patents on CNS Drug Discovery
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-04-01
- Volume
- 7
- Issue
- 1
- Pages
- 25-40
- ISSN
- 1574-8898 (ISSN-L)
- OpenAlex
- W1993041600
- Cited by
- 89
- References
- 56
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabinoid-related Agents in the Treatment of Anxiety Disorders: Current Knowledge and Future Perspectives. https://app.cochat.ai/papers/10.2174/157488912798842269
- The paper
- Tambaro, S., & Bortolato, M. (2012). Cannabinoid-related Agents in the Treatment of Anxiety Disorders: Current Knowledge and Future Perspectives. Recent Patents on CNS Drug Discovery. https://doi.org/10.2174/157488912798842269
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.